Enzymatica AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.
Enzymatica AB (EN9) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, Enzymatica AB (EN9) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Enzymatica AB - Net Assets Trend (None–None)
This chart illustrates how Enzymatica AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Enzymatica AB (None–None)
The table below shows the annual net assets of Enzymatica AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Enzymatica AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Enzymatica AB Competitors by Market Cap
The table below lists competitors of Enzymatica AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
5341
KLSE:5341
|
$1.74K |
|
Monks Investment Trust PLC
LSE:MNKS
|
$1.74K |
|
Kool2play SA
WAR:K2P
|
$1.74K |
|
Safetech Innovations SA
RO:SAFE
|
$1.74K |
|
Lanka Walltiles PLC
CM:LWLN0000
|
$1.73K |
|
Kelyniam Global Inc
PINK:KLYG
|
$1.73K |
|
Thanh Nam Group JSC
VN:TNI
|
$1.73K |
|
Live Motion Games S.A.
WAR:LMG
|
$1.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enzymatica AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Enzymatica AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Enzymatica AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Enzymatica AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enzymatica AB (EN9) | €- | N/A | N/A | $1.74K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |